The Marlborough, MA-based company said it could pick up a CE mark for the endoscopic ablation system sometime in mid-2019.
A team from Brigham and Women’s Hospital are developing a test that can detect tau protein, a calling card for Alzheimer’s disease.
The technology was designed by Northwestern Medicine along with Northwestern’s McCormick School of Engineering scientists and has the potential to monitor, separately and accurately, UVB and UVA exposure for people at high risk for melanoma.
The Menlo Park, CA-based company’s 50,000-patient trial will launch in 2019 and could be one of the most significant events of the year for the liquid biopsy market.
University of Bristol Medical School Researchers led a study that shows cemented metal-on-plastic hip replacements less than 36 mm in diameter are the most cost-effective in patients older than 65.
JenaValve has received a nod from FDA to expand enrollment in an IDE of its TAVR system. The measure comes at a time when the TAVR landscape is expected to shift.
The small startup will now be able to compete against Medtronic’s MiniMed 670g, but there are other technologies still in development that could have an even greater impact on the market.
The Redwood City, CA-based company’s financing raise is the perfect example of the strength and support the robotics market now commands in healthcare.
Teva Pharmaceuticals received approval for a generic version of Mylan’s EpiPen back in August, which came on the heels of a shortage of the emergency allergy shot. The generic gives another option to users.
The Dublin-based company will pick up Nutrino, a frequent collaborator and a company that uses artificial intelligence for nutrition-related services.
Right now we’re in the middle of the Artificial Intelligence Renaissance for medtech. But what does this mean for companies? Is this a fad or is AI here to stay in medtech. MD+DI Managing Editor Omar Ford gives his thoughts on this emerging trend.
RenalytixAI has raised $29 million to help advance tests for early detection of kidney disease and a test that will help in the accurate management of kidney transplant rejection.